Phase IIB Clinical Trial of Voclosporin Successfully Achieves Primary Endpoint

Good news posted yesterday on the Lupus Foundation of America website. To see the full article please click here.

“(Washington DC – August 15)  Today Aurinia Pharmaceutical Company announced positive top-line results of a Phase IIB clinical study of voclosporin, a potential new therapy option for people with active lupus nephritis (lupus-related kidney disease).  The study met its primary endpoint of achieving complete remission in a statistically significant number of study participants who received voclosporin. More details about this study are available through the company’s news release.

LUPUS EUROPE Uniting people with Lupus throughout Europe